Hongji Medical

Hongji Medical's product line pairs testing instruments with companion reagents: instruments are placed once in hospital laboratories or independent testing centers, after which recurring reagent consumption generates repeat revenue — a model giving the business a pronounced installed-base effect, where a larger fleet of instruments produces more stable, predictable reagent revenue over time. The product range covers routine biochemistry and immunoassay testing, with customers concentrated among prefecture-level hospitals and regional independent laboratories in lower-tier cities, alongside a growing presence in some tertiary hospitals.

R&D spending is concentrated on incremental improvements to reagent sensitivity and instrument reliability, along with a small number of new test panels targeting specific disease areas; the company maintains a staged pipeline rather than pursuing many projects in parallel. Sales cover the national market through a combination of a direct team and regional distributors, with distributor reach into lower-tier markets an important driver of installed-base growth. Reagents account for a rising share of revenue relative to instruments, reflecting the natural evolution of the model once an installed base reaches sufficient scale.

At the time of the 2019 investment, Hongji Medical had already built a meaningful installed base and reagent revenue was entering an acceleration phase, but its capital needs for pipeline expansion, channel coverage and manufacturing capacity outpaced what its own cash flow could support — the situation the growth investments strategy is built to address: a business already validated by the market, entering rapid revenue and profit expansion, needing capital to accelerate deployment rather than a fundamental governance restructuring.

The minority structure preserved the founding team's control over R&D direction and product prioritization, which matters particularly in in-vitro diagnostics, a field highly dependent on specialized technical judgment, where excessive external intervention can undermine product decisions. Capital was directed primarily at expanding manufacturing capacity and deepening channel coverage, with post-investment support helping the company grow its installed base while maintaining growth discipline.

In-vitro diagnostics continues to penetrate deeper into the domestic healthcare system, with testing moving from large tertiary hospitals toward prefecture-level hospitals and primary care institutions, while independent testing centers provide an outlet beyond hospital channels. The installed-base-and-reagent model gives early movers a degree of customer stickiness, but the field has many participants, and commoditization and price competition are evident in some routine categories; differentiation tends to come from channel depth and product reliability rather than any single breakthrough. Changes in policy, including insurance cost controls and centralized procurement, continue to shape pricing and channel structure.

Havrion Capital holds a minority position in Hongji Medical, functioning as a capital partner for this growth stage rather than a governance lead. Post-investment work focuses on helping plan the pace of capacity expansion, weigh priorities in channel development, and contribute views on financial discipline at the board level, while R&D direction and product decisions remain entirely with the founding team.